Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), and as such is thought to play an important role in the regulation of extracellular matrix remodeling. In blood, PAI-1 is bound to the adhesion protein vitronectin and is associated with vitronectin in fibrin clots and the provisional matrix. Elevated levels of PAI-1 are associated with atherosclerosis and an increased thrombotic tendency, while PAI-1 deficiency leads to increased fibrinolysis and bleeding. PAI-1 is also elevated in many solid tumors and is associated with a poor prognosis in cancer. PAI-1 has been shown to be a potent regulator of both vascular cell migration in vitro and of angiogenesis and tumor growth in vivo. PAI-1 can both promote and inhibit tumor growth and angiogenesis. Low concentrations of PAI-1 can stimulate tumor angiogenesis while treatment of animals with high doses of PAI-1 inhibits angiogenesis and tumor growth. Hence, PAI-1 appears to have a multifunctional role in regulating the migratory and fibrinolytic activity of vascular cells, and this, in turn, may help to explain the many varied actions of PAI-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“Remodeling of the extracellular matrix has been suggested to be essential for the migratory events required for angiogenesis [73] and since uPA is localized to the leading edge of migrating cells [74], it would appear that regulation of uPA activity by PAI-1 would lead to an inhibition of angiogenesis and hence tumor…”
BackgroundIntegrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., & Quaranta, V. (1997) · Science · doi:10.1126/science.277.5323.225 · Cited by 1,221 · cited 2×
“within the matrix that are important for cell adhesion and migration [81,82,103-105].”
BackgroundHouck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127 · cited 2×
“matrix [107-110].”
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Saksela, O., & Rifkin, D. B. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.3.767 · Cited by 539
Sato, Y., Tsuboi, R., Lyons, R., Moses, H., & Rifkin, D. B. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.2.757 · Cited by 444 · cited 3×
“TGFβ [62,106], or by the release of sequestered growth factors such as FGF and VEGF from the”
BackgroundHøgåsen, K., Mollnes, T. E., & Harboe, M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50058-2 · Cited by 73
Cited by
Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes
Webber, J. P., Spary, L. K., Sanders, A. J., Chowdhury, R., Jiang, W. G., Steadman, R., Wymant, J., Jones, A. T., Kynaston, H., Mason, M. D., et al. (2015) · Oncogene · doi:10.1038/onc.2013.560 · Cited by 438
Evolving role of uPA/uPAR system in human cancers
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.005 · Cited by 423
Clearance of apoptotic and necrotic cells and its immunological consequences
Krysko, D. V., D’Herde, K., & Vandenabeele, P. (2006) · Apoptosis · doi:10.1007/s10495-006-9527-8 · Cited by 316
“Moreover, using microarray analysis it was demonstrated that several genes involved in angiogenesis, such as endothelin-1, plasminogen activator inhibitor and nitric oxide synthase 2 [148–151] were upregulated following engulfment of apoptotic cells, while inhibitors of angiogenesis, endostatin and von Hippel-Lindau t…”
MethodPleiotropic functions of plasminogen activator inhibitor-1
LIJNEN, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00827.x · Cited by 312
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Metadata
- Authors
- Stefansson, S., McMahon, G., Petitclerc, E., & Lawrence, D.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-07-01
- Volume
- 9
- Issue
- 19
- Pages
- 1545-1564
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2124245160
- Cited by
- 169
- References
- 8
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.